NDATOPICALLOTION
Approved
Mar 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
ELOCON (mometasone furoate) by Merck & Co. is clinical pharmacology like other topical corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties. First approved in 1989.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELOCON (mometasone furoate) is a topical medium-potency corticosteroid that reduces inflammation, itching, and vascularity through inhibition of phospholipase A2 and downstream prostaglandin/leukotriene biosynthesis. It is used to treat inflammatory skin conditions such as atopic dermatitis and psoriasis. The drug is available as a cream and lotion formulation for direct cutaneous application.
LOE Approaching
As LOE approaches, commercial teams will transition focus toward lifecycle management, generic competition mitigation, and next-generation formulation development; team restructuring and headcount reduction are typical in this phase.
Mechanism of Action
CLINICAL PHARMACOLOGY Like other topical corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the…
Worked on ELOCON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.